Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand
- PMID: 17360332
- PMCID: PMC1829229
- DOI: 10.1073/pnas.0700682104
Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand
Abstract
The corticotropin releasing factor (CRF) family of ligands and their receptors coordinate endocrine, behavioral, autonomic, and metabolic responses to stress and play additional roles within the cardiovascular, gastrointestinal, and other systems. The actions of CRF and the related urocortins are mediated by activation of two receptors, CRF-R1 and CRF-R2, belonging to the B1 family of G protein-coupled receptors. The short-consensus-repeat fold (SCR) within the first extracellular domain (ECD1) of the CRF receptor(s) comprises the major ligand binding site and serves to dock a peptide ligand via its C-terminal segment, thus positioning the N-terminal segment to interact with the receptor's juxtamembrane domains to activate the receptor. Here we present the 3D NMR structure of ECD1 of CRF-R2beta in complex with astressin, a peptide antagonist. In the structure of the complex the C-terminal segment of astressin forms an amphipathic helix, whose entire hydrophobic face interacts with the short-consensus-repeat motif, covering a large intermolecular interface. In addition, the complex is characterized by intermolecular hydrogen bonds and a salt bridge. These interactions are quantitatively weighted by an analysis of the effects on the full-length receptor affinities using an Ala scan of CRF. These structural studies identify the major determinants for CRF ligand specificity and selectivity and support a two-step model for receptor activation. Furthermore, because of a proposed conservation of the fold for both the ECD1s and ligands, this structure can serve as a model for ligand recognition for the entire B1 receptor family.
Conflict of interest statement
Conflict of interest statement: W.W.V. is a cofounder, consultant, equity holder, and member of the Board of Directors of Neurocrine Biosciences and Acceleron Pharma. The following have been licensed by The Salk Institute for Biological Studies and/or The Clayton Foundation: CRF to Ferring Pharmaceuticals, CRF1 receptor and Ucn 2 to Neurocrine Biosciences, and Ucn 3 to Johnson & Johnson.
Figures



Similar articles
-
The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.Ann N Y Acad Sci. 2006 Jul;1070:105-19. doi: 10.1196/annals.1317.065. Ann N Y Acad Sci. 2006. PMID: 16888152
-
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.Biochemistry. 2004 Apr 6;43(13):3996-4011. doi: 10.1021/bi036110a. Biochemistry. 2004. PMID: 15049707
-
NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.J Biol Chem. 2010 Dec 3;285(49):38580-9. doi: 10.1074/jbc.M110.121897. Epub 2010 Sep 15. J Biol Chem. 2010. PMID: 20843795 Free PMC article.
-
Corticotropin releasing factor receptors and their ligand family.Ann N Y Acad Sci. 1999 Oct 20;885:312-28. doi: 10.1111/j.1749-6632.1999.tb08687.x. Ann N Y Acad Sci. 1999. PMID: 10816663 Review.
-
Members of CRF family and their receptors: from past to future.Curr Med Chem. 2011;18(17):2583-600. doi: 10.2174/092986711795933704. Curr Med Chem. 2011. PMID: 21568890 Review.
Cited by
-
Structural and Functional Insights into CRF Peptides and Their Receptors.Biology (Basel). 2024 Feb 13;13(2):120. doi: 10.3390/biology13020120. Biology (Basel). 2024. PMID: 38392338 Free PMC article. Review.
-
Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.Eur J Pharmacol. 2015 Sep 15;763(Pt B):196-205. doi: 10.1016/j.ejphar.2015.05.013. Epub 2015 May 14. Eur J Pharmacol. 2015. PMID: 25981303 Free PMC article. Review.
-
Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides.J Mol Neurosci. 2008 Nov;36(1-3):254-9. doi: 10.1007/s12031-008-9058-6. Epub 2008 Apr 12. J Mol Neurosci. 2008. PMID: 18409024 Free PMC article.
-
Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.J Biol Chem. 2008 Nov 21;283(47):32900-12. doi: 10.1074/jbc.M805749200. Epub 2008 Sep 17. J Biol Chem. 2008. PMID: 18801728 Free PMC article.
-
Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor.Front Endocrinol (Lausanne). 2018 Feb 20;9:43. doi: 10.3389/fendo.2018.00043. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29515519 Free PMC article.
References
-
- Vale W, Spiess J, Rivier C, Rivier J. Science. 1981;213:1394–1397. - PubMed
-
- Armario A. CNS Neurol Disord Drug Targets. 2006;5:485–501. - PubMed
-
- Madden J, Newton S. Clin J Oncol Nurs. 2006;10:659–661. - PubMed
-
- Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee K-F. Nat Gen. 2000;24:410–414. - PubMed
-
- Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikjian LM, Gold L, Chen R, Marchuk Y, Hauser C, Bentley CA, et al. Neuron. 1998;20:1093–1102. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases